Tamoxifen and the risk of Parkinsonism: a case/non-case study

被引：8

作者：

Montastruc, Francois ^{[1
,2
,3
,4
]}

Khosrow-Khavar, Farzin ^{[5
,6
]}

de Germay, Sibylle ^{[1
,2
,7
]}

Renoux, Christel ^{[5
,6
,8
]}

Rousseau, Vanessa ^{[2
,3
,4
,7
]}

Durrieu, Genevieve ^{[2
,3
]}

Montastruc, Marion ^{[9
]}

Rascol, Olivier ^{[1
,2
,4
,10
]}

Sommet, Agnes ^{[1
,2
,4
,7
,10
]}

Lapeyre-Mestre, Maryse ^{[1
,2
,4
,7
,10
]}

Benevent, Justine ^{[1
,2
,3
,7
]}

Montastruc, Jean-Louis ^{[1
,2
,3
,4
,7
,10
]}

机构：

[1] Univ Toulouse, Lab Pharmacol Med & Clin, Fac Med, 37 Allees Jules Guesde, F-31000 Toulouse, France

[2] CHU Toulouse, Serv Pharmacol Med & Clin, Toulouse, France

[3] CHU Toulouse, Ctr Reg PharmacoVigilance Pharmacoepidemiol & Inf, Toulouse, France

[4] CHU Toulouse, NeuroToul Ctr Excellence Neurodegenerat, Toulouse, France

[5] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada

[6] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada

[7] Univ Toulouse, Fac Med Toulouse, INSERM UMR 1027, Toulouse, France

[8] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada

[9] Inst Univ Canc Toulouse Oncopole, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France

[10] Univ Toulouse, CHU Toulouse, CIC INSERM 1436, Toulouse, France

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2018年 / 74卷 / 09期

基金：

欧盟地平线“2020”;

关键词：

Tamoxifen; Parkinsonism; Adverse drug reaction; Pharmacovigilance; Drug safety; DRUG-INDUCED PARKINSONISM; RESEARCH DATABASE; COMPETITION BIAS; BREAST-CANCER; PHARMACOVIGILANCE; DISEASE; SAFETY; FRANCE;

D O I：

10.1007/s00228-018-2496-3

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background Three studies have suggested a potential positive association between the use of tamoxifen in breast cancer and Parkinsonism, mainly after long-term exposure. Objectives To explore this potential signal, we performed a case/non-case study using the World Health Organization Global Individual Case Safety Reports (ICSRs) database, VigiBaseA (R) between 1979 and 2018. Results Among women >= 55 years, we measured the risk of reporting "Parkinsonism" compared with all other adverse drug reactions [as a reporting odds ratio (ROR 95% CI)] for tamoxifen compared to all other drugs or aromatase inhibitors. Conclusion During the study period, 356 ICSRs of Parkinsonism reported with tamoxifen were identified. We failed to find a positive association between tamoxifen exposure and Parkinsonism in comparison with exposure to other drugs (ROR = 0.79; 95% CI 0.71-0.88) or aromatase inhibitors (ROR = 0.39; 95% CI 0.33-0.46). This study did not find evidence for Parkinsonism associated with tamoxifen.

引用

页码：1181 / 1184

页数：4

共 19 条

[1] The possible role of estrogen and selective estrogen receptor modulators in a rat model of Parkinson's disease [J].